ISSN: 0278-0232

Journal Home

Journal Guideline

Hematological Oncology Q2 Unclaimed

John Wiley and Sons Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Hematological Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 54. It has a price of 3333 €. It has an SJR impact factor of 0,82 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,82.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q2) Hematology (Q2) Medicine (miscellaneous) (Q2) Oncology (Q2)

Price

3333 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,82

SJR Impact factor

54

H Index

143

Total Docs (Last Year)

344

Total Docs (3 years)

5325

Total Refs

778

Total Cites (3 years)

271

Citable Docs (3 years)

2.29

Cites/Doc (2 years)

37.24

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Clinical Rheumatology Q2
Pharmacological Reports Q2
Journal of Human Nutrition and Dietetics Q2
Diseases of the Colon and Rectum Q2
Oncology Reports Q2

Compare this journals

Aims and Scope

Best articles by citations

der(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatment

Rapid detection of t(15;17)(q24;q21) in acute promyelocytic leukaemia by microwave-assisted fluorescencein situhybridization

Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation

Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients

Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions

Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada

Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis

Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line

Peripheral T-cell lymphoma with unusual clinical presentation of rhabdomyolysis

Increased expression of AML1-a and acquired chromosomal abnormalities in childhood acute lymphoblastic leukemia

Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma

Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis

SHOW MORE ARTICLES

Mucosal dysbiosis in patients with gastrointestinal follicular lymphoma

Current and future use of hematopoietic growth factors in cancer medicine

A review of the trends of lymphomas in the equatorial belt of Africa

Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line

Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider

Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial

Factors affecting remission and survival in patients with advanced hodgkin's disease treated with MVPP

Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience

Bone mineral density (BMD) in patients with lymphoma: The effects of chemotherapy, intermittent corticosteroids and premature menopause

Cladribine-based salvage regimen-induced deep remission of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in leukemia phase